FATE
Fate Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.48
+2.48%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 69.74x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 1.94x
- Price / sales
- 45.78x
- Price / cash flow
- -2.91x
Enterprise value
- Enterprise value
- $219.1M
- EV / sales
- 33.75x
- EV / EBITDA
- -1.87x
- EV / EBIT
- -1.64x
- Market cap
- $297.2M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026